Post by PharmaShots

Takeda presents P-III (FirstLight & RadiantLight) data at SLEEP 2026 showing oveporexton improves daily functioning, cognition, and nighttime sleep in narcolepsy type 1, supporting its potential as the first orexin agonist to redefine the standard of care Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #takeda #oveporexton #phaseiii #firstlight #radiantlight #narcolepsytype1 #usfda #clinicaltrial #priorityreview #sleep2026 #fini #cognition https://lnkd.in/ea3GeYmp